Company: BFRG
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001641172-25-006297
Chunk: 42

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 42
---
 rights and defending intellectual property-related 
 claims;                                                                                                                                          |
| ● | the                                                                                                                                              
 extent to which we acquire or in-license other products and technologies and the costs to be able to obtain regulatory approval of               
 such products;                                                                                                                                   |
| ● | our                                                                                                                                              
 ability to establish strategic collaborations and licensing or other arrangements on terms favorable to us; and                                  |
| ● | competing                                                                                                                                        
 technological and market developments.                                                                                                           |

| 7 |

Any additional fundraising efforts may divert our management from their day to day activities, which may adversely affect our ability to identify and acquire new drug candidates and to further the regulatory process of such products. Our ability to raise additional funds will depend, in part, on the success of our product development activities and other factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurance that we will be able to raise additional capital when needed or on terms that are favorable to us, if at all. If adequate funds are not available on a timely basis, we may be forced to:

| ● | delay,                                                                                                                            
 reduce the scope of or eliminate one or more of our drug development programs;                                                    |
| ● | limit                                                                                                                             
 the amount of new products that we acquire or relinquish, license or otherwise dispose of rights on terms that are less favorable 
 than if we were able to further the regulatory approval process; or                                                               |
| ● | liquidate                                                                                                                         
 and dissolve the Company.                                                                                                         |

If our operating plans change, we may require additional capital sooner than planned. Such additional financing may not be available when needed or on terms favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current and future operating plan.

We are increasingly dependent on information technology systems to operate our business and a cyber-attack or other breach of our systems, or those of third parties on whom we may rely, could subject us to liability or interrupt the operation of our business.

We are increasingly dependent on information technology systems to operate our business. A breakdown, invasion, corruption, destruction or interruption of critical information technology systems by employees, others with authorized access to our systems or unauthorized persons could negatively impact operations. In the ordinary course of business, we collect, store and transmit confidential information and it is critical that we do so in a secure manner to maintain the confidentiality and integrity of such information. Additionally, we outsource certain elements of our information technology systems to third